July 16, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA grants traditional approval to Retevmo for RET fusion-positive solid tumors
The FDA has granted traditional approval to selpercatinib for adults and children aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion.Selpercatinib (Retevmo, Eli Lilly & Co.), an oral kinase inhibitor, received approval for treatment of patients with RET fusion-positive tumors, as detected by an FDA-approved test, who have progressed on or following
491 words~2 min read
